Baylor Endowment Shines Per WSJ

959 Views | 7 Replies | Last: 2 mo ago by Aliceinbubbleland
Aliceinbubbleland
How long do you want to ignore this user?
The Small University Endowment That Is Beating the Ivy League

https://www.wsj.com/finance/investing/the-small-university-endowment-that-is-beating-the-ivy-leagues-8ce37cf1?st=a0avjdebah7f9xa&reflink=desktopwebshare_permalink
william
How long do you want to ignore this user?
hmmmm... we've been at $2B for a while now.....

how much are we taking out annually???

PA.

- CFA UL

Go Bears!!
Go Bears!
Aliceinbubbleland
How long do you want to ignore this user?
Good question. I thought we were well under $2B. Nevertheless nice to finally see positive media. Do we have a BOR member with too close ties to WSJ?
RD2WINAGNBEAR86
How long do you want to ignore this user?
Am glad Baylor is thriving and not missing my pocket change.
"Never underestimate Joe's ability to **** things up!"

-- Barack Obama
LIB,MR BEARS
How long do you want to ignore this user?
RD2WINAGNBEAR86 said:

Am glad Baylor is thriving and not missing my pocket change.

I went to get my granddaughter cotton candy at the women's hoops game. They had it priced at $9.

You're welcome
TJ55
How long do you want to ignore this user?
Nice to see endowment CIO Dave Morehead and Private Equity Director Renee Hanna interviewed on Friday's CNBC Fast Money Halftime segment.......
william
How long do you want to ignore this user?
Moody Bible College MBA is a bid odd, tho, no??

- KKM

Go Bears!

Go Bears!
Aliceinbubbleland
How long do you want to ignore this user?
TJ55 said:

Nice to see endowment CIO Dave Morehead and Private Equity Director Renee Hanna interviewed on Friday's CNBC Fast Money Halftime segment.......
Hey thanks. I record the show every day but do not always watch. Appreciate the heads up as I would have missed this segment. I'm watching it now. Dave is a very impressive spokesperson.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.